A familial Alzheimer's genetic panel for someone over 65 tests the APP, PSEN1, and PSEN2 genes for the rare mutations that cause early-onset, inherited Alzheimer's disease. The test itself costs around $990 before insurance, but what a patient actually pays — and whether a doctor will even order it — depends heavily on family history and the reason for testing. This matters for readers managing dementia risk or care decisions, because the answer is different depending on whether the question is about diagnosing a relative already showing symptoms, screening a healthy adult whose parent or sibling carried a known mutation, or qualifying for a newer Alzheimer's drug. Each of those paths has its own cost, coverage rule, and referral path.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the panel actually tests and what it costs
- Who should actually be referred for this test
- How Medicare and Medicare Advantage handle coverage
- Where APOE testing fits into drug eligibility
- Frequently Asked Questions
What the panel actually tests and what it costs
The familial Alzheimer's panel sequences three genes — APP, PSEN1, and PSEN2 — whose mutations cause autosomal-dominant, early-onset Alzheimer's disease. PreventionGenetics lists the test at a base price of $990, with a 25% surcharge for STAT (rush) processing. A broader dementia panel that includes these same three genes plus additional genes linked to other dementia types is priced the same, $990. That list price is not what most patients pay out of pocket.
A University of Wisconsin genetic-counseling training presentation estimates typical U.S. out-of-pocket cost at $0 to $1,000, usually landing around $300 once insurance negotiates or applies a discount. Results typically take about three weeks to return. This test is distinct from APOE genotyping, which looks at a risk-modifying gene rather than a disease-causing mutation. The two get confused often, but they answer different questions and have different coverage rules, covered in Section 3.
Who should actually be referred for this test
Testing guidelines don't recommend this panel for everyone with a dementia diagnosis or a family history of Alzheimer's in general. The 2011 ACMG/NSGC joint practice guideline limits the appropriate candidates to three groups: a person with early-onset Alzheimer's symptoms and a family history of dementia, someone whose family history is unknown (for example, an adopted individual), or a relative of someone with an already-identified familial mutation. For most people over 65 with typical late-onset Alzheimer's and no strong family pattern of early disease, this panel isn't the relevant test — the mutations it detects almost always cause onset well before age 65, often in a patient's 40s or 50s.
A referral makes the most sense when a parent, sibling, or child developed Alzheimer's symptoms unusually early, or when a family mutation is already documented and a relative wants to know their own status before making medical or life decisions. Before any predictive test proceeds in a relative who is not yet symptomatic, the guideline requires pretest counseling on the risk of insurance discrimination affecting health, life, and disability coverage. If a symptomatic patient appears averse to testing, the guideline recommends banking the DNA instead of proceeding, preserving the option to test later.
- Symptomatic patient with early-onset Alzheimer's and a family history of dementia
- Patient with unknown family history (e.g., adopted)
- Blood relative of someone with a confirmed familial mutation
How Medicare and Medicare Advantage handle coverage
Original Medicare has no national coverage determination for APOE ε4 genotyping, and most Medicare Administrative Contractors have not covered it, even though the CMS registry required for coverage of anti-amyloid drugs like lecanemab doesn't mandate reporting APOE4 status. That gap is under active dispute: in 2026, ACMG, the Association for Molecular Pathology, and the College of American Pathologists jointly petitioned the MolDX/National Government Services Medicare contractor to remove APOE from its non-covered test list, arguing it meets Medicare's "reasonable and necessary" standard when used to flag risk before starting anti-amyloid therapy. Whether NGS has finalized that change is not yet confirmed. Coverage of the APP/PSEN1/PSEN2 panel itself is narrower and plan-specific.
A Medicare Advantage medical policy from Paramount/Elite restricts coverage to cases where genetic counseling has occurred, no prior test in the family has already identified the mutation, the family history documents autosomal-dominant dementia, and the results are intended to inform reproductive decisions. That policy explicitly does not cover testing ordered solely to confirm an existing diagnosis. For a reader over 65, that reproductive-decision requirement is worth noting directly: it means a Medicare Advantage plan built on this model may deny the panel for an older patient even when every other criterion — counseling, family history, no prior family result — is met, simply because reproductive planning doesn't apply. Checking the specific plan's policy language before scheduling the test avoids a denied claim.
Where APOE testing fits into drug eligibility
APOE genotyping is a separate test from the familial panel, and it has become relevant for a different reason: eligibility for anti-amyloid drugs. Lecanemab's (Leqembi) FDA prescribing information states that APOE ε4 genotyping should be performed before starting treatment to inform patients of their risk of ARIA, amyloid-related imaging abnormalities — a labeling detail directly relevant to patients over 65, since that age group makes up the drug's primary eligible population.
Some commercial insurers go further than the FDA label and make APOE testing a precondition for authorizing lecanemab or donanemab. Aetna's clinical policy bulletin sets this requirement and also sets a minimum patient age of 50 for commercial-plan coverage of these anti-amyloid therapies. A reader on a commercial plan considering one of these drugs should expect the APOE test to be requested as part of the authorization process, separate from any familial Alzheimer's panel discussion.
- Familial panel (APP/PSEN1/PSEN2): diagnostic for inherited, early-onset Alzheimer's
- APOE genotyping: risk-modifier test, now tied to anti-amyloid drug safety monitoring
- Medicare: no national coverage for APOE; familial panel coverage is plan-specific
- Commercial plans: may require APOE testing before authorizing lecanemab or donanemab
Frequently Asked Questions
Is the familial Alzheimer's panel the same as APOE testing?
No. The panel sequences APP, PSEN1, and PSEN2 for disease-causing mutations; APOE genotyping checks a separate risk-modifying gene and is now tied to anti-amyloid drug safety monitoring.
Will Medicare pay for either test?
Original Medicare has no national coverage determination for APOE testing, and most contractors don't cover it. Coverage of the familial panel under Medicare Advantage depends on the plan's specific medical policy.
Does a family history of typical late-onset Alzheimer's qualify someone for this panel?
Not on its own. The guideline targets early-onset cases, unknown family history, or relatives of someone with an already-identified familial mutation.
